文献速递慢性肾脏病肾血管病与高血压

新型降糖药心血管结局试验按eGFR分层的系统评价

Systematic Review of Cardiovascular Outcome Trials Using New Antidiabetic Agents in CKD Stratified by Estimated GFR.
PubMed 文献 · Kidney Int Rep · 2021-07-01

该系统评价纳入16项心血管结局试验(共150,816例,其中28.2% eGFR<60),按eGFR分层分析新型降糖药对主要心血管事件(MACE)的影响。结果显示,eGFR<60时仅SGLT-2抑制剂显著降低MACE(RR 0.85,95%CI 0.75-0.95,P=0.005);GLP-1类似物在eGFR<60时RR 0.90但无统计学意义,作者认为可能因效能不足。

要点

  • eGFR<60时SGLT-2抑制剂显著降低MACE风险(RR 0.85)。
  • GLP-1类似物在eGFR<60时MACE风险降低但无统计学意义。
  • DPP-4抑制剂在eGFR≥60和<60时对MACE均无显著影响。

核心结论

  • 在eGFR<60 ml/min per 1.73 m2的糖尿病患者中,目前仅有明确证据支持SGLT-2抑制剂可预防MACE。
  • GLP-1类似物在eGFR<60时效应量与eGFR≥60时相似,提示可能因效能不足而非无效。

研究设计与样本

  • 纳入16项心血管结局试验(GLP-1类似物6项、DPP-4抑制剂4项、SGLT-2抑制剂6项),共150,816例参与者。
  • 按试验入组时eGFR和蛋白尿分层,采用随机效应模型估计总体风险比(RR)。

主要发现

  • GLP-1类似物:eGFR≥60时MACE的RR为0.87(95%CI 0.77-0.98;P=0.02),eGFR<60时RR为0.90(95%CI 0.78-1.04;P=0.14)。
  • DPP-4抑制剂:eGFR≥60时MACE的RR为0.99(95%CI 0.92-1.07;P=0.86),eGFR<60时RR为0.99(95%CI 0.91-1.08;P=0.86)。
  • SGLT-2抑制剂:eGFR≥60时MACE的RR为1.01(95%CI 0.92-1.10;P=0.87),eGFR<60时RR为0.85(95%CI 0.75-0.95;P=0.005)。
  • 多数分析存在显著异质性;蛋白尿数据不足,无法进行实证分析。

关键数值与推荐

  • eGFR<60 ml/min per 1.73 m2的糖尿病患者使用SGLT-2抑制剂可显著降低MACE风险(RR 0.85,95%CI 0.75-0.95,P=0.005)。
  • GLP-1类似物在eGFR<60时MACE风险降低无统计学意义(RR 0.90,95%CI 0.78-1.04,P=0.14)。
  • DPP-4抑制剂在eGFR≥60和<60时对MACE均无显著影响(RR均为0.99)。

临床怎么用

  • 对于eGFR<60 ml/min per 1.73 m2的糖尿病患者,优先考虑使用SGLT-2抑制剂以降低MACE风险。
  • GLP-1类似物在肾功能不全患者中的心血管获益尚需更多证据,但效应量提示可能有效。
  • DPP-4抑制剂在肾功能不全患者中未显示MACE预防作用。

局限性

  • 多数分析存在显著异质性。
  • 蛋白尿数据不足,无法分析蛋白尿分层的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Cardiovascular benefits observed with new antidiabetic agents may not extend to chronic kidney disease (CKD) patients. This study performed a systematic review and meta-analysis of cardiovascular outcome trials (CVOTs) using new antidiabetic agents stratified by kidney function. METHODS: MEDLINE (via PubMed) and the Cochrane Central Register of Controlled Trials were searched for eligible studies up to November 16, 2020. Data were stratified by the trial entry estimated glomerular filtration rate (eGFR) and albuminuria. Primary major cardiovascular event (MACE) outcomes were extracted, and a meta-analysis with a random effects model was performed to estimate overall risk ratios (RRs). RESULTS: Our search identified 16 studies for inclusion (glucagon-like peptide-1 [GLP-1] analogues, n = 6; dipeptidyl-peptidase 4 [DPP-4] inhibitors, n = 4; and sodium-glucose cotransporter-2 [SGLT-2] inhibitors, n = 6) with a combined total of 150,816 participants (28.2% with eGFR <60 ml/min per 1.73 m2, n = 42,534). The RR for MACE with GLP-1 analogues with an eGFR ≥60 ml/min per 1.73 m2 was 0.87 (95% confidence interval [CI], 0.77-0.98; P = 0.02) and 0.90 (95% CI, 0.78-1.04; P = 0.14) with an eGFR <60 ml/min per 1.73 m2. The RR for MACE with DPP-4 inhibitors with eGFR ≥60 ml/min per 1.73 m2 was 0.99 (95% CI, 0.92-1.07; P = 0.86) and 0.99 (95% CI, 0.91-1.08; P = 0.86) with an eGFR <60 ml/min per 1.73 m2. The RR for MACE with SGLT-2 inhibitors with an eGFR ≥60 ml/min per 1.73 m2 was 1.01 (95% CI, 0.92-1.10; P = 0.87) and 0.85 (95% CI, 0.75-0.95; P = 0.005) with an eGFR <60 ml/min per 1.73 m2. Most analyses had significant heterogeneity. Sufficient albuminuria data were unavailable to analyze empirically. CONCLUSION: Clear evidence for MACE prevention in diabetes patients with an eGFR <60 ml/min per 1.73 m2 currently exists for SGLT-2 inhibitors only. However, similar GLP-1 analogue effect sizes suggest a lack of sufficient power rather than a lack of effect.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Arshad A, Sarween N, Sharif A, et al. Systematic Review of Cardiovascular Outcome Trials Using New Antidiabetic Agents in CKD Stratified by Estimated GFR. Kidney Int Rep. 2021. PMID: 34514202. doi:10.1016/j.ekir.2021.06.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。